Widding the Use of Insulin Sensitizers to Patients with Polycystic Ovarian Syndrome—A Late, but Wise Decision

Marcos Felipe Silva de Sá

doi:10.1055/s-0039-1685482

Revista Brasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, Table of Contents

CC BY 4.0 · Rev Bras Ginecol Obstet 2019; 41(03): 137-141
DOI: 10.1055/s-0039-1685482

Editorial

Thieme Publicações Ltda Rio de Janeiro, Brazil

Widding the Use of Insulin Sensitizers to Patients with Polycystic Ovarian Syndrome—A Late, but Wise Decision

Ampliando o uso de sensibilizadores de insulina às pacientes com síndrome do ovário policístico – Atrasada, mas uma sábia decisão

Marcos Felipe Silva de Sá

¹Department of Gynecology and Obstetrics, Faculty of Medicine, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

› Author Affiliations

Abstract

Full Text

References

References
1 Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25 . Doi: 10.1016/j.fertnstert.2003.10.004
2 Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26 (07) 883-896 . Doi: 10.1038/sj.ijo.0801994
3 Penaforte FRO, Japur CC, Diez-Garcia RW, Chiarello PG. Upper trunk fat assessment and its relationship with metabolic and biochemical variables and body fat in polycystic ovary syndrome. J Hum Nutr Diet 2011; 24 (01) 39-46 . Doi: 10.1111/j.1365-277X.2010.01130.x
4 Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2004; 82 (03) 661-665 . Doi: 10.1016/j.fertnstert.2004.01.041
5 Hoeger KM, Oberfield SE. Do women with PCOS have a unique predisposition to obesity?. Fertil Steril 2012; 97 (01) 13-17 . Doi: 10.1016/j.fertnstert.2011.11.026
6 Georgopoulos NA, Saltamavros AD, Vervita V. , et al. Basal metabolic rate is decreased in women with polycystic ovary syndrome and biochemical hyperandrogenemia and is associated with insulin resistance. Fertil Steril 2009; 92 (01) 250-255 . Doi: 10.1016/j.fertnstert.2008.04.067
7 Moran LJ, Noakes M, Clifton PM. , et al. Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab 2004; 89 (07) 3337-3344 . Doi: 10.1210/jc.2003-031583
8 Hirschberg AL, Naessén S, Stridsberg M, Byström B, Holtet J. Impaired cholecystokinin secretion and disturbed appetite regulation in women with polycystic ovary syndrome. Gynecol Endocrinol 2004; 19 (02) 79-87 . Doi: 10.1080/09513590400002300
9 Moran LJ, Noakes M, Clifton PM. , et al. Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. Am J Clin Nutr 2007; 86 (06) 1603-1610 . Doi: 10.1093/ajcn/86.5.1603
10 Barber TM, Casanueva FF, Karpe F. , et al. Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur J Endocrinol 2008; 158 (04) 511-516 . Doi: 10.1530/EJE-07-0683
11 Harrold JA, Dovey TM, Blundell JE, Halford JC. CNS regulation of appetite. Neuropharmacology 2012; 63 (01) 3-17 . Doi: 10.1016/j.neuropharm.2012.01.007
12 Kanoski SE. Cognitive and neuronal systems underlying obesity. Physiol Behav 2012; 106 (03) 337-344 . Doi: 10.1016/j.physbeh.2012.01.007
13 Zwirska-Korczala K, Sodowski K, Konturek SJ. , et al. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J Physiol Pharmacol 2008; 59 (Suppl. 02) 161-178
14 Lin T, Li S, Xu H. , et al. Gastrointestinal hormone secretion in women with polycystic ovary syndrome: an observational study. Hum Reprod 2015; 30 (11) 2639-2644 . Doi: 10.1093/humrep/dev231
15 Neary NM, Small CJ, Druce MR. , et al. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 2005; 146 (12) 5120-5127 . Doi: 10.1210/en.2005-0237
16 Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93 (07) 2670-2678 . Doi: 10.1210/jc.2008-0115
17 Tanaka K, Saisho Y, Kawai T. , et al. Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocr J 2015; 62 (05) 399-409 . Doi: 10.1507/endocrj.EJ14-0602
18 Liu X, Zhang Y, Zheng SY. , et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. Clin Endocrinol (Oxf) 2017; 87 (06) 767-774 . Doi: 10.1111/cen.13454
19 Tsilchorozidou T, Batterham RL, Conway GS. Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). Clin Endocrinol (Oxf) 2008; 69 (06) 936-942 . Doi: 10.1111/j.1365-2265.2008.03285.x
20 Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol 2005; 184 (02) 291-318 . Doi: 10.1677/joe.1.05866
21 Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50 (08) 1714-1719 . Doi: 10.2337/diabetes.50.8.1714
22 Micic D, Sumarac-Dumanovic M, Kendereski A. , et al. Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome. J Endocrinol Invest 2007; 30 (10) 820-827 . Doi: 10.1007/BF03349222
23 Schöfl C, Horn R, Schill T, Schlösser HW, Müller MJ, Brabant G. Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87 (10) 4607-4610 . Doi: 10.1210/jc.2002-020505
24 Waśko R, Komarowska H, Warenik-Szymankiewicz A, Sowiński J. Elevated ghrelin plasma levels in patients with polycystic ovary syndrome. Horm Metab Res 2004; 36 (03) 170-173 . Doi: 10.1055/s-2004-814341
25 Japur CC, Diez-Garcia RW, de Oliveira Penaforte FR, de Sá MFS. Imbalance between postprandial ghrelin and insulin responses to an ad libitum meal in obese women with polycystic ovary syndrome. Reprod Sci 2014; 21 (08) 1020-1026 . Doi: 10.1177/1933719114522521
26 Wright CE, Zborowski JV, Talbott EO, McHugh-Pemu K, Youk A. Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord 2004; 28 (08) 1026-1032 . Doi: 10.1038/sj.ijo.0802661
27 Reaven GM. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu Rev Nutr 2005; 25: 391-406 . Doi: 10.1146/annurev.nutr.24.012003.132155
28 Bruner B, Chad K, Chizen D. Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl Physiol Nutr Metab 2006; 31 (04) 384-391 . Doi: 10.1139/h06-007
29 Norman RJ, Davies MJ, Lord J, Moran LJ. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13 (06) 251-257 . Doi: 10.1016/S1043-2760(02)00612-4
30 Hoeger KM. Exercise therapy in polycystic ovary syndrome. Semin Reprod Med 2008; 26 (01) 93-100 . Doi: 10.1055/s-2007-992929
31 Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90 (12) 6364-6369 . Doi: 10.1210/jc.2005-1490
32 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18 (06) 774-800 . Doi: 10.1210/edrv.18.6.0318
33 Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. ; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91 (01) 48-53 . Doi: 10.1210/jc.2005-1329
34 Buchanan TA, Xiang AH, Peters RK. , et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51 (09) 2796-2803
35 Knowler WC, Barrett-Connor E, Fowler SE. , et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346 (06) 393-403 . Doi: 10.1056/NEJMoa012512
36 Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89: 505-522 . Doi: 10.1016/j.fertnstert.2007.09.041
37 Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Consensus on women's health aspects of polycystic ovary syndrome (PCOS). Hum Reprod 2012; 27: 14-12 . Doi: 10.1093/humrep/der396
38 Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance?. Fertil Steril 2012; 97 (01) 18-22 . Doi: 10.1016/j.fertnstert.2011.11.036
39 Wild RA, Carmina E, Diamanti-Kandarakis E. , et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95 (05) 2038-2049 . Doi: 10.1210/jc.2009-2724
40 Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. ; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease state clinical review: guide to the best practices in the evaluation and treatment of Polycystic Ovary Syndrome–part 1. Endocr Pract 2015; 21 (11) 1291-1300 . Doi: 10.4158/EP15748.DSC
41 Geller DH, Pacaud D, Gordon CM, Misra M. ; of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 2011; 2011: 9 . Doi: 10.1186/1687-9856-2011-9
42 Silfen ME, Denburg MR, Manibo AM. , et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003; 88 (10) 4682-4688 . Doi: 10.1210/jc.2003-030617
43 Hsia Y, Dawoud D, Sutcliffe AG, Viner RM, Kinra S, Wong IC. Unlicensed use of metformin in children and adolescents in the UK. Br J Clin Pharmacol 2012; 73 (01) 135-139 . Doi: 10.1111/j.1365-2125.2011.04063.x
44 Barber TM, Wass JA, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 66 (04) 513-517 . Doi: 10.1111/j.1365-2265.2007.02764.x
45 Horwitz RI, Hayes-Conroy A, Caricchio R, Singer BH. From evidence based medicine to medicine based evidence. Am J Med 2017; 130 (11) 1246-1250 . Doi: 10.1016/j.amjmed.2017.06.012
46 Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R. Use of metformin in polycystic ovary syndrome. Am J Obstet Gynecol 2008; 199 (06) 596-609 . Doi: 10.1016/j.ajog.2008.09.010
47 Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab 2008; 93 (11) 4299-4306 . Doi: 10.1210/jc.2008-0461
48 Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012; 30 (06) 496-506 . Doi: 10.1055/s-0032-1328878
49 Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121 (02) 149-157.e2 . Doi: 10.1016/j.amjmed.2007.09.016
50 Soares Júnior JM, Sa MF, Baracat EC. [Should insulin resistance be always treated in Polycystic Ovary Syndrome?]. Rev Bras Ginecol Obstet 2014; 36 (02) 47-49 . Doi: 10.1590/S0100-72032014000200001
51 Teede HJ, Misso ML, Costello MF. , et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril 2018; 110 (03) 364-379 . Doi: 10.1016/j.fertnstert.2018.05.004
52 Hurliman A, Keller Brown J, Maille N, Mandala M, Casson P, Osol G. Hyperandrogenism and insulin resistance, not changes in body weight, mediate the development of endothelial dysfunction in a female rat model of Polycystic Ovary Syndrome (PCOS). Endocrinology 2015; 156 (11) 4071-4080 . Doi: 10.1210/en.2015-1159
53 Radenković M. Pioglitazone and endothelial dysfunction: pleiotropic effects and possible therapeutic implications. Sci Pharm 2014; 82 (04) 709-721 . Doi: 10.3797/scipharm.1407-16
54 Romero R, Erez O, Hüttemann M. , et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol 2017; 217 (03) 282-302 . Doi: 10.1016/j.ajog.2017.06.003